Lackepila

Lacosamide, the active ingredient in Lackepila, is an anticonvulsant presented as an oral tablet for oral use. It belongs to the sodium‑channel blocker class and is employed to treat partial‑onset seizures in patients with epilepsy, helping to reduce seizure frequency and improve quality of life.

GNH USA supplies Lackepila as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and providing reliable global distribution.

Lacosamide is an anticonvulsant indicated for seizure disorders within the epilepsy disease family.

- Partial-onset seizures: reduces seizure frequency as adjunctive therapy in patients with focal epilepsy. - Focal epilepsy: provides additional seizure control when first‑line agents are insufficient. - Adjunctive therapy for refractory seizures: enhances overall seizure management in patients not fully controlled by other antiepileptics.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild to moderate upset stomach. - Headache: occasional throbbing pain. - Fatigue: feeling unusually tired. - Blurred vision: temporary visual disturbances. - Diplopia: double vision in some patients.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, especially in patients with pre‑existing conduction disorders. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal ideation: emergence of thoughts of self‑harm. - Hypersensitivity: including rash, angioedema, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzymes or liver injury. - Respiratory depression: slowed breathing in severe cases.

Before initiating therapy, clinicians should consider several safety factors.

- Renal impairment: adjust dosage in patients with severe renal dysfunction. - Hepatic impairment: monitor liver function tests regularly. - Cardiac conduction disorders: avoid use in patients with known PR‑interval prolongation or other significant conduction abnormalities. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Driving and operating machinery: caution patients about dizziness or visual changes that may affect performance. - Store at ambient temperature: keep below 25 °C, protect from moisture, and retain in the original packaging.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce lacosamide effectiveness. - Concurrent use with other sodium‑channel blockers: heightened risk of cardiac conduction effects.

Moderate Interactions (Monitor Closely): - Alcohol: may exacerbate central nervous system depression. - Hormonal contraceptives: lacosamide may reduce contraceptive efficacy. - Other antiepileptic drugs: dose adjustments may be needed based on therapeutic response. - Antihypertensive agents: monitor blood pressure as additive effects are possible. - Antidepressants: watch for increased risk of mood changes.